Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
2017年10月20日 - 4:04AM
ビジネスワイヤ(英語)
Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN:
JP3300600008) and Innovation Network Corporation of Japan (“INCJ”)
today announced the close of their joint acquisition of Ambry
Genetics Corporation (“Ambry”) on October 19, 2017 (JST). Known as
a pioneer and thought leader in genetic testing, Ambry is the first
laboratory in the world to offer hereditary cancer panels and
clinical exome sequencing.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171019006403/en/
This strategic acquisition was announced on July 6, 2017.
Through this acquisition, Konica Minolta and INCJ will accelerate
the precision medicine business by creating a new medical platform
to improve patients’ quality of life while also saving the
healthcare system money.
Ambry chose to partner with Konica Minolta to accelerate the
development of new diagnostic tests for many different diseases for
patients throughout the world. Together they have the combined
resources, technology, and scale to advance biomedical research on
a global scale, resulting in better tests for doctors and more
precise treatments for their patients.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital
technology company with core strengths in imaging and data
analysis, optics, materials, and nano-fabrication. Through
innovation, we create products and digital solutions for the
betterment of business and society—today and for generations to
come. Across our Business Technologies, Healthcare, and
Industrial-facing businesses, we aspire to be an Integral Value
Provider that applies the full range of our company’s expertise to
offer comprehensive solutions to our customer’s most pressing
problems, work with our partners to ensure our solutions are
sustainable, anticipate and address tomorrow’s issues, and tailor
each solution to meet the unique and specific needs of our valued
customers. Leveraging these capabilities, Konica Minolta
contributes to productivity improvement and workflow change for our
customers, and provides leading-edge service solutions in the IoT
era.
Headquartered in Tokyo and with operations in more than 50
countries, Konica Minolta has more than 43,000 employees serving
approximately two million customers in over 150 countries. Konica
Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/.
About INCJ
INCJ was established in July 2009 as a public-private investment
company that provides financial, technological and management
support for next-generation businesses. INCJ specifically supports
those projects that combine technologies and varied expertise
across industries and materialize open innovation. INCJ has the
capacity to invest up to JPY2 trillion (approx. US$20 billion).
INCJ’s management team is drawn from the private sector with
diverse experience in investment, technologies and management.
Through its Innovation Network Committee, INCJ assesses investment
opportunities that contribute to industrial innovation in Japan in
line with criteria set by the government. For more information
please see: http://www.incj.co.jp/english/.
About Ambry Genetics
Since 1999, Ambry’s mission has remained focused on
understanding disease so cures can come faster. Today, Ambry
remains unwavering in its commitment to being tough, innovative,
committed to quality and, most of all, focused to do what is right
for patient care. For more information on Ambry’s full suite of
genetic testing, visit http://www.ambrygen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171019006403/en/
Konica MinoltaKonica Minolta Inc., Corporate
Communications
Dept.press@konicaminolta.com+81-3-6250-2100orInnovation Network
Corporation of JapanINCJ Group PR:Irie,
Sakai+81-3-5218-7202